NovoCure (NVCR) Accounts Payables (2014 - 2026)

NovoCure (NVCR) has reported Accounts Payables for 13 consecutive years, with $130.7 million the latest figure, recorded in Q2 2026.

• Quarterly Accounts Payables rose 26.09% year-over-year to $130.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $130.7 million (up 26.09% YoY) and the FY2025 annual result came in at $122.2 million, up 16.32% from the prior year.
• Accounts Payables climbed to $130.7 million in Q2 2026 per NVCR's latest filing, from $127.2 million in the prior quarter.
• Over the last five years, Accounts Payables for NVCR reached as high as $130.7 million in Q2 2026 and fell as low as $69.2 million in Q1 2022.
• A 5-year average of $95.5 million and a median of $90.7 million in 2024 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2022 — Accounts Payables soared 40.72% — and 2023, when it advanced 3.29%.
• Year by year, Accounts Payables stood at $85.2 million in 2022, then advanced by 10.79% to $94.4 million in 2023, then gained by 11.33% to $105.1 million in 2024, then grew by 16.32% to $122.2 million in 2025, then advanced by 6.95% to $130.7 million in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $130.7 million, $127.2 million, and $122.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.